Take a sneak peek at the new NIST.gov and let us know what you think!
(Please note: some content may not be complete on the beta site.).
NIST Authors in Bold
|Author(s):||Illarion V. Turko; Junjun J. Chen; Irina Pikuleva;|
|Title:||Mass spectrometry quantification of PICALM and AP180 in human frontal cortex and neural retina|
|Published:||August 13, 2013|
|Abstract:||Recent genome-wide association studies have suggested that endocytic factors, such as phosphatidylinositol-binding clathrin assembly protein (PICALM), may be implicated in the development of Alzheimer disease (AD). The cellular functions of PICALM are in line with this possibility: (i) PICALM is involved in regulation of amyloid-β levels and (ii) PICALM is important for a presynaptic function, which is diminished in AD. To facilitate the analysis of PICALM, we developed a quantitative method to assess the expression level of PICALM in various biological samples. For this purpose, a stable isotope-labeled quantification concatamer (QconCAT) of PICALM was designed, expressed, purified, and characterized. The PICALM QconCAT was first used as an internal standard in a multiple reaction monitoring assay to measure PICALM concentrations in the human frontal cortex, a tissue strongly affected by AD. A second endocytic factor that is highly homologous to PICALM and also functions in clathrin-mediated endocytosis, clathrin coat assembly protein AP180, was quantified as well. Because age-related macular degeneration shares several clinical and pathological features with AD, the measurements were then extended to human normal neural retina. Overall, the developed method is suitable for PICALM and AP180 quantitative analysis in various biological samples of interest.|
|Pages:||pp. 253 - 258|
|Keywords:||multiple reaction monitoring, mass spectrometry, QconCAT, quantification, Alzheimer's disease, PICALM|
|Research Areas:||Organic Analytical Chemistry|
|DOI:||http://dx.doi.org/110.1016/j.ab.2013.08.005 (Note: May link to a non-U.S. Government webpage)|